OMass Therapeutics raises $310M for genetic adrenal disorder treatment
UK biotech OMass Therapeutics collected $310 million in one of the largest private financings for a British biotech in recent years, seeking to develop treatments for congenital adrenal hyperplasia and compete with Neurocrine and Vertex.
3 sourcesCongenital Adrenal Hyperplasia
00